Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 15000 participants.
Also called NCT05169021
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 15,000 participants
- Sponsor
- Registry
-
NCT05169021
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05169021. Randomized; no masking; primary purpose prevention. Start 2021-12-31 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
- Acronym
- FAITH
- Condition
- Cerebral Small Vessel Diseases
- Condition
- Stroke
- Intervention (Drug)
- Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
- Intervention (Drug)
- Amlodipine folic acid 5.8mg+standard antihypertensive therapy
- Intervention (Drug)
- Amlodipine+intensive antihypertensive therapy
- Intervention (Drug)
- Amlodipine+standard antihypertensive therapy
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05169021- Content hash
b785f1339f2cd377dfb48c9051a92ba35f5e82734f4665fa29c261c35958fad4